Company Filing History:
Years Active: 2022-2025
Title: Innovations of Shu Wen Samantha Ho
Introduction
Shu Wen Samantha Ho is a prominent inventor based in Singapore, known for his significant contributions to the field of biotechnology. He holds a total of 4 patents that focus on advanced antigen-binding molecules, which have the potential to revolutionize cancer treatment.
Latest Patents
His latest patents include an "Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137." This invention provides antigen-binding domains capable of binding to CD3 and CD137, but not simultaneously, along with methods to obtain these domains more efficiently. Another notable patent is the "CD137- and DLL3-targeting multispecific antigen-binding molecules." This invention features multispecific antigen-binding molecules that can bind to CD3 and CD137 without simultaneous binding, as well as a third moiety that binds to DLL3, enhancing T-cell dependent cytotoxicity while minimizing adverse effects.
Career Highlights
Shu Wen Samantha Ho is currently associated with Chugai Seiyaku Kabushiki Kaisha, where he continues to innovate in the field of biotechnology. His work focuses on developing therapeutic solutions that address critical health challenges, particularly in oncology.
Collaborations
He collaborates with notable colleagues such as Tomoyuki Igawa and Sotaro Naoi, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Shu Wen Samantha Ho's work exemplifies the intersection of science and innovation, particularly in the development of targeted therapies for cancer treatment. His contributions are paving the way for future advancements in biotechnology.